Company news
KalVista Pharmaceuticals, Inc. news in 2021
KalVista Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.
KalVista Pharmaceuticals Provides Progress Update on KVD900 for Oral On-Demand Treatment of Hereditary Angioedema
November 9, 2021
KalVista Pharmaceuticals Presents Data Demonstrating KVD900 Achieves Rapid Exposure and Improves Outcomes as Oral On-Demand Treatment of HAE
November 7, 2021
KalVista Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference
September 20, 2021
KalVista Pharmaceuticals Announces the Lifting of FDA Clinical Hold for Phase 2 Trial of KVD824
September 13, 2021
KalVista Pharmaceuticals Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema
August 22, 2021
KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE
July 11, 2021
KalVista Pharmaceuticals to Present Data at the European Academy of Allergy and Clinical Immunology (EAACI)
June 27, 2021
KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop
June 4, 2021
KalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
May 26, 2021
KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K. Audhya, MD, MBA as Chief Medical Officer
May 2, 2021
KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824
April 19, 2021
KalVista Pharmaceuticals Appoints Nancy Stuart to Board of Directors
March 18, 2021
KalVista Pharmaceuticals Announces the Closing of its Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
February 15, 2021
KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock
February 9, 2021
KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock
February 8, 2021